Table 1.

Characteristics of all patients according to EGFR mutation status

EGFR mutation status
P
MutationWild-type
No. patients17510.8
Age (range)60 (34-84)59 (39-86)
Sex (%)
    Male6 (35.3)39 (76.5)0.003
    Female11 (64.7)12 (23.5)
Histology (%)
    Adenocarcinoma17 (100)30 (58.8)0.007
    Large cell carcinoma5 (9.8)
    Squamous cell carcinoma11 (21.6)
    Other5 (9.8)
Smoking history (%)
    Smokers3 (17.6)43 (84.3)0.0001
    Nonsmokers14 (82.4)8 (15.7)
No. prior regimens (range)1 (0-3)2 (0-6)0.04
Response to gefitinib (%)
    Complete and partial response16 (94.1)6 (11.8)<0.0001
    Stable disease1 (5.9)8 (15.7)
    Progressive disease34 (66.7)
    Not evaluable3 (5.8)
Duration of gefitinib treatment
    Months (range)9.4 (1.1-23.1)4.2 (0.2-41.9)0.07